SUPPLEMENT

Q2 2023 — Recast other financial disclosures

Q2 2023PDF · 17 pages1.0 MB
Table 1: Sales by Geographic Area - 2023 	1
Table 1a: Sales by Geographic Area - 2022 	2
Table 2: Condensed Consolidated Statement of Earnings - 2023 	3
Table 2a: Condensed Consolidated Statement of Earnings - 2022 	4
Table 3: Non-GAAP Adjusted Net Earnings - 2023 	5
Table 3a: Non-GAAP Adjusted Net Earnings - 2022 	6
Table 4: Non-GAAP Adjusted Operational Sales Growth - 2023 	7
Table 4a: Non-GAAP Adjusted Operational Sales Growth - 2022 	8
Table 5: Non-GAAP IBT by Segment - Q1 2023 	9
Table 5a: Non-GAAP IBT by Segment - Q2 2023 	10
Table 5b: Non-GAAP IBT by Segment - Q1 2022 	11
Table 5c: Non-GAAP IBT by Segment - Q2 2022 	12
Table 5d: Non-GAAP IBT by Segment - Q3 2022 	13
Table 5e: Non-GAAP IBT by Segment - Q4 2022 	14
Table 6: Non-GAAP P&L Reconciliation - 2023 	15
Table 6a: Non-GAAP P&L Reconciliation - 2022 	16
August 30, 2023
Restated Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	10,782	$ 	9,857 	9.4 % 	9.4 	-
Europe 	5,590 	5,341 	4.7 	9.4 	(4.7)
Western Hemisphere excluding U.S. 	1,076 	998 	7.8 	15.5 	(7.7)
Asia-Pacific, Africa 	3,446 	3,644 	(5.4) 	3.1 	(8.5)
International 	10,112 	9,983 	1.3 	7.7 	(6.4)
Worldwide 	20,894	$ 	19,840 	5.3 % 	8.5 	(3.2)
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,657	$ 	10,510 	10.9 % 	10.9 	-
Europe 	5,131 	5,355 	(4.2) 	(5.2) 	1.0
Western Hemisphere excluding U.S. 	1,136 	1,027 	10.7 	16.8 	(6.2)
Asia-Pacific, Africa 	3,595 	3,323 	8.2 	14.3 	(6.1)
International 	9,862 	9,705 	1.6 	3.8 	(2.2)
Worldwide 	21,519	$ 	20,215 	6.5 % 	7.5 	(1.0)
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	22,439	$ 	20,367 	10.2 % 	10.2 	-
Europe 	10,721 	10,696 	0.2 	2.1 	(1.9)
Western Hemisphere excluding U.S. 	2,212 	2,025 	9.3 	16.2 	(6.9)
Asia-Pacific, Africa 	7,041 	6,967 	1.1 	8.5 	(7.4)
International 	19,974 	19,688 	1.5 	5.8 	(4.3)
Worldwide 	42,413	$ 	40,055 	5.9 % 	8.0 	(2.1)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
Percent Change
FIRST QUARTER
Percent Change
SECOND QUARTER
Percent Change
SIX MONTHS

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	9,857	$ 	9,500 	3.8 % 	3.8 	-
Europe 	5,341 	4,727 	13.0 	21.2 	(8.2)
Western Hemisphere excluding U.S. 	998 	968 	3.0 	4.2 	(1.2)
Asia-Pacific, Africa 	3,644 	3,485 	4.6 	8.3 	(3.7)
International 	9,983 	9,180 	8.7 	14.5 	(5.8)
Worldwide 	19,840	$ 	18,680 	6.2 % 	9.1 	(2.9)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,510	$ 	10,168 	3.4 % 	3.4 	-
Europe 	5,355 	4,936 	8.5 	22.1 	(13.6)
Western Hemisphere excluding U.S. 	1,027 	933 	10.2 	13.2 	(3.0)
Asia-Pacific, Africa 	3,323 	3,421 	(2.9) 	6.2 	(9.1)
International 	9,705 	9,290 	4.5 	15.4 	(10.9)
Worldwide 	20,215	$ 	19,458 	3.9 % 	9.1 	(5.2)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,794	$ 	10,338 	4.4 % 	4.4 	-
Europe 	4,844 	4,833 	0.2 	16.1 	(15.9)
Western Hemisphere excluding U.S. 	1,059 	1,019 	3.9 	9.1 	(5.2)
Asia-Pacific, Africa 	3,299 	3,336 	(1.1) 	11.4 	(12.5)
International 	9,202 	9,188 	0.1 	13.6 	(13.5)
Worldwide 	19,996	$ 	19,526 	2.4 % 	8.7 	(6.3)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,820	$ 	10,634 	1.7 % 	1.7 	-
Europe 	5,124 	6,099 	(16.0) 	(6.3) 	(9.7)
Western Hemisphere excluding U.S. 	1,024 	1,007 	1.7 	8.3 	(6.6)
Asia-Pacific, Africa 	2,971 	3,336 	(10.9) 	3.0 	(13.9)
International 	9,119 	10,442 	(12.7) 	(1.9) 	(10.8)
Worldwide 	19,939	$ 	21,076 	(5.4) % 	(0.1) 	(5.3)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	41,981	$ 	40,640 	3.3 % 	3.3 	-
Europe 	20,664 	20,595 	0.3 	12.1 	(11.8)
Western Hemisphere excluding U.S. 	4,108 	3,927 	4.6 	8.7 	(4.1)
Asia-Pacific, Africa 	13,237 	13,578 	(2.5) 	7.2 	(9.7)
International 	38,009 	38,100 	(0.2) 	10.0 	(10.2)
Worldwide 	79,990	$ 	78,740 	1.6 % 	6.5 	(4.9)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
THIRD QUARTER
FIRST QUARTER
Percent Change
SECOND QUARTER
Percent Change
Percent Change
FOURTH QUARTER
Percent Change
TWELVE MONTHS
Percent Change

-- 3 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent 	Percent 	Percent
Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales
Sales to customers 	20,894	$ 	100.0 	21,519	$ 	100.0 	42,413	$ 	100.0
Cost of products sold 	6,687 	32.0 	6,462 	30.0 	13,149 	31.0
Gross Profit 	14,207 	68.0 	15,057 	70.0 	29,264 	69.0
Selling, marketing and administrative expenses 	4,906 	23.5 	5,396 	25.1 	10,302 	24.3
Research and development expense 	3,455 	16.6 	3,703 	17.2 	7,158 	16.9
In-process research and development Impairments 	49 	0.2 	- 	- 	49 	0.1
Interest income 	(198) 	(0.9) 	(326) 	(1.5) 	(524) 	(1.2)
Interest expense, net of portion capitalized 	212 	1.0 	217 	1.0 	429 	1.0
Other (income) expense, net 	6,940 	33.2 	(384) 	(1.8) 	6,556 	15.5
Restructuring 	130 	0.6 	145 	0.7 	275 	0.6
Earnings/(loss) before provision for taxes on income 	(1,287) 	(6.2) 	6,306 	29.3 	5,019 	11.8
Provision for/(Benefit from) taxes on income 	(796) 	(3.9) 	930 	4.3 	134 	0.3
Net earnings/(loss) from Continuing Operations 	(491)	$ 	(2.3) 	5,376	$ 	25.0 	4,885	$ 	11.5
Net earnings/(loss) from Discontinued Operations, net of tax 	423 	(232) 	191
Net earnings/(loss) 	(68)	$ 	5,144	$ 	5,076	$
Net Earnings (loss) per Share (Diluted) from Continuing Operations 	(0.19)	$ 	2.05	$ 	1.86	$
Net Earnings (loss) per Share (Diluted) from Discontinued Operations 	0.16	$ 	(0.09)	$ 	0.07	$
Average shares outstanding (Diluted) 	2,605.5 * 	2,625.7 	2,630.7
*Basic Shares used as in an overall loss position
Effective tax rate from Continuing Operations 	61.8 % 	14.7 % 	2.7 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from continuing operations 	7,536	$ 	36.1 	8,005	$ 	37.2 	15,541	$ 	36.6
Net earnings from continuing operations 	6,340	$ 	30.3 	6,730	$ 	31.3 	13,070	$ 	30.8
Net earnings per share (Diluted) from continuing operations 	2.41	$ 	2.56	$ 	4.97	$
Average shares outstanding (Diluted) 	2,634.3 	2,625.7 	2,630.7
Effective tax rate from continuing operations 	15.9 % 	15.9 % 	15.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
2023
Q1 	Q2 	SIX MONTHS

-- 4 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent 	Percent 	Percent 	Percent 	Percent 	Percent
Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales
Sales to customers 	19,840	$ 	100.0 	20,215	$ 	100.0 	40,055	$ 	100.0 	19,996	$ 	100.0 	19,939	$ 	100.0 	79,990	$ 	100.0
Cost of products sold 	6,018 	30.3 	6,322 	31.3 	12,340 	30.8 	6,172 	30.9 	6,084 	30.5 	24,596 	30.7
Gross Profit 	13,822 	69.7 	13,893 	68.7 	27,715 	69.2 	13,824 	69.1 	13,855 	69.5 	55,394 	69.3
Selling, marketing and administrative expenses 	4,812 	24.3 	5,120 	25.3 	9,932 	24.8 	4,975 	24.9 	5,339 	26.8 	20,246 	25.3
Research and development expense 	3,355 	16.9 	3,585 	17.7 	6,940 	17.3 	3,485 	17.4 	3,710 	18.6 	14,135 	17.7
In-process research and development Impairments 	610 	3.1 	- 	- 	610 	1.5 	- 	- 	173 	0.8 	783 	1.0
Interest income 	(22) 	(0.1) 	(64) 	(0.3) 	(86) 	(0.2) 	(150) 	(0.8) 	(254) 	(1.3) 	(490) 	(0.6)
Interest expense, net of portion capitalized 	10 	0.1 	38 	0.2 	48 	0.1 	51 	0.3 	177 	0.9 	276 	0.3
Other (income) expense, net 	(210) 	(1.1) 	(1) 	0.0 	(211) 	(0.5) 	226 	1.1 	795 	4.0 	810 	1.0
Restructuring 	64 	0.3 	71 	0.4 	135 	0.4 	65 	0.3 	75 	0.4 	275 	0.4
Earnings before provision for taxes on income 	5,203 	26.2 	5,144 	25.4 	10,347 	25.8 	5,172 	25.9 	3,840 	19.3 	19,359 	24.2
Provision for taxes on income 	632 	3.2 	882 	4.3 	1,514 	3.7 	862 	4.3 	613 	3.1 	2,989 	3.7
Net earnings from Continuing Operations 	4,571 	23.0 	4,262	$ 	21.1 	8,833	$ 	22.1 	4,310	$ 	21.6 	3,227	$ 	16.2 	16,370	$ 	20.5
Net earnings from Discontinued Operations, net of tax 	578 	552 	1,130 	148 	293 	1,571
Net earnings 	5,149	$ 	4,814	$ 	9,963	$ 	4,458	$ 	3,520	$ 	17,941	$
Net Earnings per Share (Diluted) from Continuing Operations 	1.71	$ 	1.60	$ 	3.31	$ 	1.62	$ 	1.22	$ 	6.14	$
Net Earnings per Share (Diluted) from Discontinued Operations 	0.22	$ 	0.20	$ 	0.42	$ 	0.06	$ 	0.11	$ 	0.59	$
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,669.2 	2,661.3 	2,650.1 	2,663.9
Effective tax rate from Continuing Operations 	12.1 % 	17.1 % 	14.6 % 	16.7 % 	16.0 % 	15.4 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from continuing operations 	7,349	$ 	37.0 	7,082	$ 	35.0 	14,431	$ 	36.0 	7,060	$ 	35.3 	6,482	$ 	32.5 	27,973	$ 	35.0
Net earnings from continuing operations 	6,388	$ 	32.2 	6,038	$ 	29.9 	12,426	$ 	31.0 	5,938	$ 	29.7 	5,432	$ 	27.2 	23,796	$ 	29.7
Net earnings per share (Diluted) from continuing operations 	2.40	$ 	2.26	$ 	4.66	$ 	2.23	$ 	2.05	$ 	8.93	$
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,669.2 	2,661.3 	2,650.1 	2,663.9
Effective tax rate from continuing operations 	13.1 % 	14.7 % 	13.9 % 	15.9 % 	16.2 % 	14.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
2022
Q1 	Q2 	SIX MONTHS 	Q3 	Q4 	FULL YEAR

-- 5 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	Q1 	Q2 	SIX MONTHS
Net Earnings/(loss) from Continuing Operations, after tax - as reported 	($491) 	$5,376 	$4,885
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,122 	1,130 	2,252
Litigation related 	6,900 	137 	7,037
IPR&D impairments 	49 	0 	49
Restructuring related 	130 	145 	275
Acquisition, integration and divestiture related 	42 	38 	80
(Gains)/losses on securities 	72 	(1) 	71
Medical Device Regulation 	64 	85 	149
COVID-19 Vaccine related costs 	444 	165 	609
Tax Adjustments
Tax impact on special item adjustments 	(1,980) 	(307) 	(2,287)
Consumer Health separation tax related costs 	11 	(17) 	(6)
Tax legislation and other tax related 	(23) 	(21) 	(44)
Adjusted Net Earnings from continuing operations, after tax 	$6,340 	$6,730 	$13,070
Average shares outstanding (Diluted) 	2,634.3 	2,625.7 	2,630.7
Adjusted net earnings per share from continuing operations (Diluted) 	$2.41 	$2.56 	$4.97
2023

-- 6 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	Q1 	Q2 	Q3 	Q4 	FULL YEAR
Net Earnings from Continuing Operations, after tax - as reported 	$4,571 	$4,262 	$4,310 	$3,227 	$16,370
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,014 	995 	958 	977 	3,944
Litigation related 	0 	385 	219 	262 	866
IPR&D impairments 	610 	0 	0 	173 	783
Restructuring related 	58 	103 	92 	119 	372
Acquisition, integration and divestiture related 	0 	0 	0 	196 	196
(Gains)/losses on securities 	411 	109 	164 	6 	690
Medical Device Regulation 	60 	70 	78 	88 	296
COVID-19 Vaccine related costs 	0 	276 	377 	821 	1,474
Other 	(7) 	0 	0 	0 	(7)
Tax Adjustments
Tax impact on special item adjustments 	(346) 	(242) 	(312) 	(394) 	(1,294)
Consumer Health separation tax related costs 	96 	2 	(36) 	4 	66
Tax legislation and other tax related 	(79) 	78 	88 	(47) 	40
Adjusted Net Earnings from continuing operations, after tax 	$6,388 	$6,038 	$5,938 	$5,432 	$23,796
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,661.3 	2,650.1 	2,663.9
Adjusted net earnings per share from continuing operations (Diluted) 	$2.40 	$2.26 	$2.23 	$2.05 	$8.93
2022

-- 7 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Q2 	SIX MONTHS
WW As Reported 	5.3% 	6.5% 	5.9%
U.S. 	9.4% 	10.9% 	10.2%
International 	1.3% 	1.6% 	1.5%
WW Currency 	(3.2) 	(1.0) 	(2.1)
U.S. 	- 	- 	-
International 	(6.4) 	(2.2) 	(4.3)
WW Operational 	8.5% 	7.5% 	8.0%
U.S. 	9.4% 	10.9% 	10.2%
International 	7.7% 	3.8% 	5.8%
Abiomed 	(1.6) 	(1.6) 	(1.6)
U.S. 	(2.7) 	(2.6) 	(2.6)
International 	(0.6) 	(0.6) 	(0.6)
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0
U.S. 	0.0 	0.0 	0.0
International 	0.1 	0.2 	0.2
WW Adjusted Operational 	6.9% 	6.0% 	6.4%
U.S. 	6.7% 	8.3% 	7.6%
International 	7.2% 	3.4% 	5.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
2023 ACTUAL vs. 2022 ACTUAL
Total Enterprise
Q1

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Q2 	SIX MONTHS 	Q3 	NINE MONTHS 	Q4 	TWELVE MONTHS
WW As Reported 	6.2% 	3.9% 	5.0% 	2.4% 	4.1% 	(5.4)% 	1.6%
U.S. 	3.8% 	3.4% 	3.6% 	4.4% 	3.8% 	1.7% 	3.3%
International 	8.7% 	4.5% 	6.6% 	0.1% 	4.5% 	(12.7)% 	(0.2)%
WW Currency 	(2.9) 	(5.2) 	(4.1) 	(6.3) 	(4.8) 	(5.3) 	(4.9)
U.S. 	- 	- 	- 	- 	- 	- 	-
International 	(5.8) 	(10.9) 	(8.4) 	(13.5) 	(10.0) 	(10.8) 	(10.2)
WW Operational 	9.1% 	9.1% 	9.1% 	8.7% 	8.9% 	(0.1)% 	6.5%
U.S. 	3.8% 	3.4% 	3.6% 	4.4% 	3.8% 	1.7% 	3.3%
International 	14.5% 	15.4% 	15.0% 	13.6% 	14.5% 	(1.9)% 	10.0%
Abiomed 	(0.1)
U.S. 	(0.3)
International 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.1 	0.1 	0.1 	0.1 	0.0
U.S. 	0.0 	0.1 	0.0 	0.1 	0.0 	0.1 	0.0
International 	0.0 	0.1 	0.1 	0.1 	0.1 	0.1 	0.1
WW Adjusted Operational 	9.1% 	9.2% 	9.2% 	8.8% 	9.0% 	(0.1)% 	6.5%
U.S. 	3.8% 	3.5% 	3.6% 	4.5% 	3.8% 	1.5% 	3.3%
International 	14.5% 	15.5% 	15.1% 	13.7% 	14.6% 	(1.8)% 	10.1%
Adjusted Operational Sales Growth
2022 ACTUAL vs. 2021 ACTUAL
Note: Percentages are based on actual, non-rounded figures and may not sum
Total Enterprise
Q1

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,402 	1,409 	(7,098) 	(1,287)
% to Sales 	32.8% 	18.8% 	-34.0% 	-6.2%
Intangible asset amortization expense 	739 	383 	- 	1,122
In-process research and development Impairments 	- 	49 	- 	49
Litigation Related 	- 	- 	6,900 	6,900
Loss/(gain) on securities 	38 	34 	- 	72
Restructuring related 	130 	- 	- 	130
Acquisition, integration and divestiture related 	- 	42 	- 	42
Medical Device Regulation 	- 	64 	- 	64
COVID-19 Vaccine related costs 	444 	- 	- 	444
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,753 	1,981 	(198) 	7,536
% to Sales 	42.9% 	26.5% 	-0.9% 	36.1%
Q1 2023 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,812 	1,671 	(177) 	6,306
% to Sales 	35.0% 	21.5% 	-0.8% 	29.3%
Intangible asset amortization expense 	748 	382 	- 	1,130
In-process research and development Impairments 	- 	- 	- 	-
Litigation Related 	(93) 	60 	170 	137
Loss/(gain) on securities 	38 	(39) 	- 	(1)
Restructuring related 	145 	- 	- 	145
Acquisition, integration and divestiture related 	- 	38 	- 	38
Medical Device Regulation 	- 	85 	- 	85
COVID-19 Vaccine related costs 	165 	- 	- 	165
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,815 	2,197 	(7) 	8,005
% to Sales 	42.3% 	28.2% 	0.0% 	37.2%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	9,214 	3,080 	(7,275) 	5,019
% to Sales 	33.9% 	20.2% 	-17.2% 	11.8%
Intangible asset amortization expense 	1,487 	765 	- 	2,252
In-process research and development Impairments 	- 	49 	- 	49
Litigation Related 	(93) 	60 	7,070 	7,037
Loss/(gain) on securities 	76 	(5) 	- 	71
Restructuring related 	275 	- 	- 	275
Acquisition, integration and divestiture related 	- 	80 	- 	80
Medical Device Regulation 	- 	149 	- 	149
COVID-19 Vaccine related costs 	609 	- 	- 	609
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	11,568 	4,178 	(205) 	15,541
% to Sales 	42.6% 	27.4% 	-0.5% 	36.6%
Worldwide Total
Q2 2023 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q2 2023 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	3,873 	1,441 	(111) 	5,203
% to Sales 	30.1% 	20.7% 	-0.6% 	26.2%
Intangible asset amortization expense 	760 	254 	- 	1,014
In-process research and development Impairments 	610 	- 	- 	610
Loss/(gain) on securities 	394 	17 	- 	411
Restructuring related 	(14) 	72 	- 	58
Medical Device Regulation 	- 	60 	- 	60
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,623 	1,844 	(118) 	7,349
% to Sales 	43.7% 	26.5% 	-0.6% 	37.0%
Q1 2022 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,365 	1,110 	(331) 	5,144
% to Sales 	32.8% 	16.1% 	-1.6% 	25.4%
Intangible asset amortization expense 	736 	259 	- 	995
Litigation Related 	21 	264 	100 	385
Loss/(gain) on securities 	102 	7 	- 	109
Restructuring related 	23 	80 	- 	103
Medical Device Regulation 	- 	70 	- 	70
COVID-19 Vaccine related costs 	276 	- 	- 	276
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,523 	1,790 	(231) 	7,082
% to Sales 	41.5% 	25.9% 	-1.1% 	35.0%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	8,238 	2,551 	(442) 	10,347
% to Sales 	31.5% 	18.4% 	-1.1% 	25.8%
Intangible asset amortization expense 	1,496 	513 	- 	2,009
In-process research and development Impairments 	610 	- 	- 	610
Litigation Related 	21 	264 	100 	385
Loss/(gain) on securities 	496 	24 	- 	520
Restructuring related 	9 	152 	- 	161
Medical Device Regulation 	- 	130 	- 	130
COVID-19 Vaccine related costs 	276 	- 	- 	276
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	11,146 	3,634 	(349) 	14,431
% to Sales 	42.6% 	26.2% 	-0.9% 	36.0%
Worldwide Total
Q2 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q2 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 13 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,186 	1,090 	(104) 	5,172
% to Sales 	31.7% 	16.1% 	-0.5% 	25.9%
Intangible asset amortization expense 	698 	260 	- 	958
Litigation Related 	7 	212 	- 	219
Loss/(gain) on securities 	177 	(13) 	- 	164
Restructuring related 	23 	69 	- 	92
Medical Device Regulation 	- 	78 	- 	78
COVID-19 Vaccine related costs 	377 	- 	- 	377
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,468 	1,696 	(104) 	7,060
% to Sales 	41.4% 	25.0% 	-0.5% 	35.3%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	12,424 	3,641 	(546) 	15,519
% to Sales 	31.5% 	17.6% 	-0.9% 	25.8%
Intangible asset amortization expense 	2,194 	773 	- 	2,967
In-process research and development Impairments 	610 	- 	- 	610
Litigation Related 	28 	476 	100 	604
Loss/(gain) on securities 	673 	11 	- 	684
Restructuring related 	32 	221 	- 	253
Medical Device Regulation 	- 	208 	- 	208
COVID-19 Vaccine related costs 	653 	- 	- 	653
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	16,614 	5,330 	(453) 	21,491
% to Sales 	42.2% 	25.8% 	-0.8% 	35.8%
Worldwide Total
Q3 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q3 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 14 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	3,223 	806 	(189) 	3,840
% to Sales 	24.5% 	11.9% 	-0.9% 	19.3%
Intangible asset amortization expense 	717 	260 	- 	977
In-process research and development Impairments 	173 	- 	- 	173
Litigation Related 	76 	136 	50 	262
Loss/(gain) on securities 	23 	(17) 	- 	6
Restructuring related 	31 	88 	- 	119
Acquisition, integration and divestiture related 	(104) 	300 	- 	196
Medical Device Regulation 	- 	88 	- 	88
COVID-19 Vaccine related costs 	821 	- 	- 	821
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	4,960 	1,661 	(139) 	6,482
% to Sales 	37.7% 	24.5% 	-0.7% 	32.5%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	15,647 	4,447 	(735) 	19,359
% to Sales 	29.8% 	16.2% 	-0.9% 	24.2%
Intangible asset amortization expense 	2,911 	1,033 	- 	3,944
In-process research and development Impairments 	783 	- 	- 	783
Litigation Related 	104 	612 	150 	866
Loss/(gain) on securities 	696 	(6) 	- 	690
Restructuring related 	63 	309 	- 	372
Acquisition, integration and divestiture related 	(104) 	300 	- 	196
Medical Device Regulation 	- 	296 	- 	296
COVID-19 Vaccine related costs 	1,474 	- 	- 	1,474
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	21,574 	6,991 	(592) 	27,973
% to Sales 	41.0% 	25.5% 	-0.7% 	35.0%
Worldwide Total
Q4 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q4 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 15 of 17 --

Quarter to Date
First Quarter
April 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition,
integration and
divestiture related
Medical Device
Regulation
First Quarter
April 2, 2023
Non-GAAP
Cost of products sold 	6,687	$ 	(1,118) 	- 	(23) 	(206) 	5,340
Selling, marketing and admin expenses 	4,906 	(7) 	4,899
Research and development expense 	3,455 	(16) 	(34) 	(16) 	3,389
Other (Income) / Expense 	6,940 	(4) 	(6,900) 	- 	(26) 	(72) 	(222) 	(284)
In-process research and development Impairments 	49 	(49) 	-
Interest (Income) / Expense 	14 	14
Restructuring 	130 	(130) 	-
Provision for/(Benefit from) taxes on income 	(796) 	177 	1,622 	11 	32 	5 	16 	12 	105 	(11) 	23 	1,196
Net Earnings/(Loss) from Continuing Operations 	(491) 	945 	5,278 	38 	98 	37 	56 	52 	339 	11 	(23) 	6,340
Quarter to Date
Second Quarter
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation
Second Quarter
July 2, 2023
Non-GAAP
Cost of products sold 	6,462	$ 	(1,130) 	- 	(34) 	38 	- 	- 	5,336
Selling, marketing and admin expenses 	5,396 	(8) 	5,388
Research and development expense 	3,703 	- 	(44) 	(46) 	3,613
Other (Income) / Expense 	(384) 	- 	(137) 	- 	(38) 	1 	(156) 	- 	(714)
In-process research and development Impairments 	- 	- 	-
Interest (Income)/Expense 	(109) 	(109)
Restructuring 	145 	(145) 	-
Provision for taxes on income 	930 	177 	29 	- 	37 	12 	(1) 	15 	38 	17 	21 	1,275
Net Earnings from Continuing Operations 	5,376 	953 	108 	- 	108 	26 	- 	71 	126 	(17) 	(21) 	6,730
Year to Date
Six Months
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation
Six Months
July 2, 2023
Non-GAAP
Cost of products sold 	13,149	$ 	(2,248) 	- 	(57) 	(168) 	10,676
Selling, marketing and admin expenses 	10,302 	(15) 	10,287
Research and development expense 	7,158 	(16) 	(78) 	(62) 	7,002
Other (Income) / Expense 	6,556 	(4) 	(7,037) 	- 	(64) 	(71) 	(378) 	- 	(998)
In-process research and development Impairments 	49 	(49) 	- 	- 	-
Interest (Income)/Expense 	(95) 	(95)
Restructuring 	275 	(275) 	-
Provision for taxes on income 	134 	354 	1,651 	11 	69 	17 	15 	27 	143 	6 	44 	2,471
Net Earnings from Continuing Operations 	4,885 	1,898 	5,386 	38 	206 	63 	56 	123 	465 	(6) 	(44) 	13,070
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs

-- 16 of 17 --

Quarter to Date
First Quarter
April 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition,
integration and
divestiture related
Medical Device
Regulation 	Other
First Quarter
April 3, 2022
Non-GAAP
Cost of products sold 	6,018	$ 	(1,014) 	(14) 	(22) 	4,968
Selling, marketing and admin expenses 	4,812 	(6) 	4,806
Research and development expense 	3,355 	(32) 	3,323
Other (Income) / Expense 	(210) 	- 	- 	20 	- 	(411) 	- 	7 	(594)
In-process research and development Impairments 	610 	(610) 	-
Restructuring 	64 	(64) 	-
Provision for taxes on income 	632 	148 	(53) 	138 	8 	- 	96 	11 	- 	(96) 	79 	(2) 	961
Net Earnings from Continuing Operations 	4,571 	866 	53 	472 	50 	- 	315 	49 	- 	96 	(79) 	(5) 	6,388
Quarter to Date
Second Quarter
July 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Second Quarter
July 3, 2022
Non-GAAP
Cost of products sold 	6,322	$ 	(995) 	(14) 	(25) 	(194) 	- 	- 	- 	5,094
Selling, marketing and admin expenses 	5,120 	(6) 	5,114
Research and development expense 	3,585 	- 	(39) 	(110) 	3,436
Other (Income) / Expense 	(1) 	- 	(385) 	(18) 	- 	(109) 	28 	- 	- 	(485)
In-process research and development Impairments 	- 	- 	-
Restructuring 	71 	(71) 	-
Provision for taxes on income 	882 	148 	(29) 	- 	20 	- 	25 	13 	65 	(2) 	(78) 	- 	1,044
Net Earnings from Continuing Operations 	4,262 	847 	414 	- 	83 	- 	84 	57 	211 	2 	78 	- 	6,038
Quarter to Date
Third Quarter
Oct 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Third Quarter
Oct 2, 2022
Non-GAAP
Cost of products sold 	6,172	$ 	(958) 	(9) 	(29) 	(102) 	- 	- 	- 	5,074
Selling, marketing and admin expenses 	4,975 	(7) 	4,968
Research and development expense 	3,485 	- 	(42) 	(80) 	3,363
Other (Income) / Expense 	226 	- 	(219) 	(18) 	- 	(164) 	(195) 	- 	- 	(370)
In-process research and development Impairments 	- 	- 	-
Restructuring 	65 	(65) 	-
Provision for taxes on income 	862 	146 	(7) 	- 	19 	- 	43 	15 	96 	36 	(88) 	- 	1,122
Net Earnings from Continuing Operations 	4,310 	812 	226 	- 	73 	- 	121 	63 	281 	(36) 	88 	- 	5,938
Quarter to Date
Fourth Quarter
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Jan 1, 2023
Non-GAAP
Cost of products sold 	6,084	$ 	(977) 	(25) 	(33) 	(160) 	- 	- 	- 	4,889
Selling, marketing and admin expenses 	5,339 	(9) 	- 	5,330
Research and development expense 	3,710 	- 	(46) 	(114) 	3,550
Other (Income) / Expense 	795 	- 	(262) 	(19) 	(196) 	(6) 	(547) 	- 	- 	(235)
In-process research and development Impairments 	173 	(173) 	-
Restructuring 	75 	(75) 	-
Provision for taxes on income 	613 	148 	(36) 	40 	19 	5 	2 	17 	199 	(4) 	47 	- 	1,050
Net Earnings from Continuing Operations 	3,227 	829 	298 	133 	100 	191 	4 	71 	622 	4 	(47) 	- 	5,432
Twelve Months
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Jan 1, 2023
Non-GAAP
Cost of products sold 	24,596	$ 	(3,944) 	(62) 	(109) 	(456) 	20,025
Selling, marketing and admin expenses 	20,246 	(28) 	20,218
Research and development expense 	14,135 	- 	(159) 	(304) 	13,672
Other (Income) / Expense 	810 	- 	(866) 	(35) 	(196) 	(690) 	(714) 	- 	7 	(1,684)
In-process research and development Impairments 	783 	(783) 	- 	- 	-
Restructuring 	275 	(275) 	-
Provision for taxes on income 	2,989 	590 	(125) 	178 	66 	5 	166 	56 	360 	(66) 	(40) 	(2) 	4,177
Net Earnings from Continuing Operations 	16,370 	3,354 	991 	605 	306 	191 	524 	240 	1,114 	66 	40 	(5) 	23,796
Tax legislation and
other tax related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Year to Date
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation tax
related costs
Tax legislation and
other tax related

-- 17 of 17 --